In general, SMYD3 expression is very weak or undetectable in the majority of normal human tissues, whereas its overexpression has been implicated in the development and progression of colorectal, hepatocellular and prostate cancer [14, 15]. Here, SMYD3 is linked to prostate carcinoma.